Introduction
Inflammation is characterized initially by the local induction of coagulation accompanied by fibrin deposition.
Tissue factor (TF), a membrane protein, is considered a major trigger for the coagulation pathway (1) . Tissue factor pathway inhibitor (TFPI) is a multivalent proteinase inhibitor of TF-induced coagulation (2) . Structurally, the mature TFPI protein comprises an acidic amino-terminal domain followed by three tandem Kunitz-type domains and a basic carboxy-terminal region. The Kunitz-2 domain inhibits factor Xa. The Kunitz-1 domain is required for the inhibition of factor VII, forming a quaternary complex of Xa-TFPI/VIIa-TF. The Kunitz-3 domain or at least a portion of it is required for binding to heparin and for optimal inhibition of factor X (3-5 ) .
At sites of inflammation, neutrophils accumulate initially followed by mononuclear phagocytes at later temporal stages. Upon activation, these cells release a variety of proteins including matrix metalloproteinases (MMPs). The MMP family comprises structurally related enzymes that play a major role in tissue remodeling and repair associated with development and inflammation. Individual MMPs have by guest on http://www.jbc.org/ Downloaded from distinct substrate specificities, which may be selective or broad ( 6 ) tumor invasion (7, 8) , arthritis (9) , aneurysm (10), pulmonary emphysema (11) , and atherosclerosis (12) .
The purpose of this study was to determine if inflammatory cellderived MMPs could influence the coagulation cascade. We have found that MMP-1, -7, -9, and -12 cleave TFPI, rendering it considerably inactive.
In contrast, these MMPs did not degrade tissue factor (TF), factor VII, or 
TFPI. Recombinant human TFPI was obtained by cloning full length
human TFPI (rTFPI) cDNA with subsequent expression in Escherichia coli and purification as previously described (13) . TFPI capacity for inhibition of TF-induced coagulation was determined by standard procedure (see below).
by guest on was added to the thiopeptolide substrate, Ac-Pro-Leu-Gly-S-Leu-Leu-Gly- Chromogenic assay of TFPI anti-Xa activity. TFPI was i n c u b a t e d
with MMPs as described above, and inhibition of factor Xa activity was performed as described previously (19) .
Determination of K m and k cat .
Values for the K m and k cat of TFPI degradation by MMP-7 and MMP-12 were determined using previously described methodology (20 
Human atherosclerotic tissues.
Tissues were obtained from human carotid endarterectomy specimens. These specimens were processed for either RNA extraction or paraffin embedding as previously described (21).
Reverse transcription and polymerase chain reaction (RT-PCR).
RNA was extracted from liquid nitrogen-frozen atherosclerotic tissue using TRIzol (Life Technologies, Gaithersburg, MD). The RT-PCR reaction was performed in duplicate using RNA from two carotid endarterectomy specimens. First strand cDNA was synthesized from 1.5 µg of total RNA. 
Results
MMPs cleave TFPI but not TF, VII, and Xa. The ability of MMPs to cleave TFPI was examined. For these studies, we used recombinant bacteriaexpressed human TFPI. As shown in Figure 1a and 
Degradation by MMPs alters TFPI biologic activity. In order to assess
whether TFPI activity is altered following cleavage by MMPs, the protein was incubated with individual MMPs and assayed for its capacity to inhibit TF-mediated coagulation and factor Xa activity. Figure 5a shows that anti-coagulant activity markedly decreased when TFPI was exposed to these four MMPs. This effect was most pronounced with MMP-12. Of We and others (21) Biochemical analysis demonstrated that inflammatory cell leukocyte derived MMP-1, -7, -9, and -12 cleave TFPI but not TF, factor VII and factor Xa. The specific sites in TFPI cleaved by these MMPs were bonds with hydrophobic residues at the P1' (Table I) (27, 28) . However, the affinity of MMPs for TFPI is somewhat weaker than their affinity for matrix proteins (Table II, The finding that TFPI is susceptible to cleavage by MMPs is potentially important because it suggests a novel role for MMPs in disease states involving blood coagulation such as atherosclerosis, restenosis, and hypertension (12, 29, 30) . With respect to atherosclerosis, we (21, 31) and others (32, 33) 
